ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 9.4% on Thursday . The company traded as low as GBX 3.82 ($0.05) and last traded at GBX 3.90 ($0.05). 12,650,292 shares changed hands during trading, a decline of 36% from the average session volume of 19,725,383 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Stock Up 2.6 %
The company has a market cap of £16.58 million, a PE ratio of -6.74 and a beta of 1.53. The stock’s 50 day simple moving average is GBX 2.77 and its two-hundred day simple moving average is GBX 2.04.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Insider Buying Explained: What Investors Need to Know
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- How to buy stock: A step-by-step guide for beginners
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
- There Are Different Types of Stock To Invest In
- MarketBeat Week in Review – 02/10 – 02/14
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
